Celyad to address US institutional investors in January at J.P. Morgan Healthcare Conference

Celyad to address US institutional investors in January at J.P. Morgan Healthcare Conference

Celyad receives clearance from the US FDA on its CHART-2 Phase III IND

Celyad receives clearance from the US FDA on its CHART-2 Phase III IND

Celyad announces the publication of its CHART-1 trial design methods paper in the European Journal of Heart Failure

Celyad announces the publication of its CHART-1 trial design methods paper in the European Journal of Heart Failure

Celyad announces the appointment of Pierre Brynaert as Chief Human Resources Officer

Celyad announces the appointment of Pierre Brynaert as Chief Human Resources Officer

Celyad treats first patient of second cohort in NKG2D CAR T-CELL Phase I Trial

Celyad treats first patient of second cohort in NKG2D CAR T-CELL Phase I Trial

Letter to Shareholders - November 2015

Letter to Shareholders - November 2015

Celyad announces third quarter 2015 business update

Celyad announces third quarter 2015 business update

Celyad successfully completes 30-day safety follow-up of first patient cohort in NKG2D CAR T-Cell Phase I Trial

Celyad successfully completes 30-day safety follow-up of first patient cohort in NKG2D CAR T-Cell Phase I Trial

Celyad CEO Invited to Present at 2015 CAR-T Summit in Massachusetts.

Celyad CEO Invited to Present at 2015 CAR-T Summit in Massachusetts.

Celyad initiates the certification by the EMA of the non-clinical data of C-Cure®

Celyad initiates the certification by the EMA of the non-clinical data of C-Cure®

List of key investors events Celyad will attend in the coming months

List of key investors events Celyad will attend in the coming months

First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells (“CAR-T”) Modified to Reduce Immunogenicity is Awarded to Celyad

First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells (“CAR-T”) Modified to Reduce Immunogenicity is Awarded to Celyad